Nicotine withdrawal in the rat: Role of α7 nicotinic receptors in the ventral tegmental area

NeuroReport

Volumn 10, Issue 4, 1999, Pages 697-702

  Nomikos, George G ^a,b   Hildebrand, Bengt E ^a   Panagis, George ^a   Svensson, Torgny H ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Dopamine; Locomotor activity; Methyllycaconitine; Microdialysis; Nucleus accumbens; 7 subunit

Indexed keywords

NICOTINIC RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; LOCOMOTION; MALE; MICRODIALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; RAT; RECEPTOR DENSITY; SMOKING CESSATION; VENTRAL TEGMENTUM; WITHDRAWAL SYNDROME;

EID: 0033577176     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001756-199903170-00007     Document Type: Article

References (25)

1. 1. Hughes JR, Gust SW, Skoog K et al. Arch Gen Psych 48, 52-59 (1991).
2. 2. Hildebrand BE, Nomikos GG, Bondjers C et al. Psychopharmacology 129, 348-356 (1997).
3. 3. Clarke PBS. Mesolimbic dopamine activation-the key to nicotine reinforcement? In: Bock G and Marsh J, eds The Biology of Nicotine Dependence (Ciba Foundation Symposium 152). Chichester: Wiley, 1990: 153-168.
4. 4. Corrigall WA. Br J Addict 86, 507-510 (1991).
5. 5. Clarke PBS and Pert A. Brain Res 348, 355-358 (1985).
6. 6. Corrigall WA, Coen KM and Adamson KL. Brain Res 653, 278-284 (1994).
7. 7. Nisell M, Nomikos GG and Svensson TH. Synapse 16, 36-44 (1994).
8. 8. Hildebrand BE, Panagis G, Nomikos GG and Svensson TH. Nordic J Psych 52, 131 (1998).
9. 9. Clarke PBS, Schwartz RD, Paul SM et al. J Neurosci 5, 1307-1315 (1985).
10. 10. Dominguez del Toro E, Juiz JM, Peng X et al. J Comp Neurol 349, 325-342 (1994).
11. 11. Schilström B, Svensson HM, Svensson TH and Nomikos GG. Neuroscience 85, 1005-1009 (1998).
12. 12. Hildebrand BE, Nomikos GG, Hertel P et al. Brain Res 779, 214-225 (1998).
13. 13. Paxinos G and Watson C. The Rat Brain in Stereotaxic Coordinates. 2nd edn. San Diego: Academic Press, 1986.
14. 14. Felix R and Levin ED. Neuroscience 81, 1009-1017 (1997).
15. 15. Alkondon M, Pereira EF, Wonnacott S and Albuquerque EX. Mol Pharmacol 41, 802-808 (1992).
16. 16. Briggs CA, McKenna DG and Piattoni-Kaplan M. Neuropharmacology 34, 583-590 (1995).
17. 17. Ward JM, Cockcroft VB, Lunt GG et al. FEBS Lett 270, 45-48 (1990).
18. 18. McGehee DS, Heath MJS, Gelber S et al. Science 269, 1692-1696 (1995).
19. 19. Gray R, Rajan AS, Radcliffe KA et al. Nature 383, 713-716 (1996).
20. 20. Collins AC and Marks MJ. Drug Dev Res 38, 231-242 (1996).
21. 21. Lukas RJ, Ke L, Bencheril M and Eisenhour CM. Drug Dev Res 38, 136-148 (1996).
22. 22. Rossetti ZL, Hmaidan Y and Gessa GL. Eur J Pharmacol 221, 227-234 (1992).
23. 23. Koob GF, Stinus L, Le Moal M and Bloom FE. Neurosci Biobehav Rev 13, 135-140 (1989).
24. 24. Koob GF, Markou A, Weiss F et al. Semin Neurosci 5, 351-358 (1993).
25. 25. Epping-Jordan MP, Watkins SS, Koob GF and Markou A. Nature 393, 76-79 (1998).